A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1618-7601
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction ; day:4 ; month:12 ; year:2022 ; pages:1-14
The European journal of health economics ; (4.12.2022), 1-14
- Creator
-
Tafazzoli, Ali
Reifsnider, Odette S.
Bellanca, Leana
Ishak, Jack
Carrasco, Marc
Rakonczai, Pal
Stargardter, Matthew
Linden, Stephan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10198-022-01555-6
- URN
-
urn:nbn:de:101:1-2023021421195248857534
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tafazzoli, Ali
- Reifsnider, Odette S.
- Bellanca, Leana
- Ishak, Jack
- Carrasco, Marc
- Rakonczai, Pal
- Stargardter, Matthew
- Linden, Stephan
- SpringerLink (Online service)
Other Objects (12)
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
Right ventricular ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
Right ventricular ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
Right ventricular ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction